Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385)

🧪 Interventions in This Study

• Adavosertib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Medical Center-Mount Zion — San Francisco, California
• UCSF Medical Center-Mission Bay — San Francisco, California
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia
• Northwestern University — Chicago, Illinois
• University of Chicago Comprehensive Cancer Center — Chicago, Illinois
• UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
• University of Chicago Medicine-Orland Park — Orland Park, Illinois
• University of Kansas Clinical Research Center — Fairway, Kansas
• University of Kansas Cancer Center — Kansas City, Kansas
• University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
• Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts
• Brigham and Women's Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
• Weisberg Cancer Treatment Center — Farmington Hills, Michigan
• Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
• Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
• Washington University School of Medicine — St Louis, Missouri
• Siteman Cancer Center-South County — St Louis, Missouri
• Siteman Cancer Center at Christian Hospital — St Louis, Missouri
• Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Clear Cell Renal Cell Carcinoma

• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery — Fairbanks, Alaska
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — Los Angeles, California
• Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors — Duarte, California
• A Phase 1/2 Trial of ADI-270 in ccRCC — Redwood City, California
• Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab — Iowa City, Iowa
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer — Westwood, Kansas

Explore by condition: All Clear Cell Renal Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.